Medpace (MEDP)
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
$591.29-0.35%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
Intact: The reason to own it still holds.
Medpace grows revenue about 6% a year, backed by strong backlog and new business. Profit margins improve with operating income rising to $141.5 million in Q1 2026. Net income grows steadily, reaching $123.9 million in Q1 2026. The company maintains stable management and delivers consistent earnings beats.
Revenue growth could slow below 6%, hurting earnings momentum. Operating income gains may stall due to rising costs or inefficiencies. Leadership changes could disrupt execution and strategic focus.
The market expects about 7% revenue growth and values the stock slightly above consensus estimates. Our view aligns with this growth but sees risks if execution falters or growth slows.
Breaks if: Significant management disruption harms execution or strategy
Breaks if: Net income falls below $123.9 million in Q1 2026
Drive net income growth through revenue expansion and operational efficiency to improve earnings per share.
Net income growth has been a stated priority in 5 quarters from 2025-Q2 to 2026-Q2. GAAP net income rose from $90.3M in 2025-Q2 to $121.4M in 2026-Q2, with diluted EPS increasing from $3.10 to $4.25. The company’s 2026 EPS guidance of $17.25 to $17.95 supports continued net income growth, indicating delivery on this priority.
“GAAP net income was $121.4 million in Q2 2026, or $4.25 per diluted share.”
“GAAP net income was $123.9 million in Q1 2026, or $4.28 per diluted share.”
“GAAP net income was $135.1 million in Q4 2025, or $4.67 per diluted share.”
“GAAP net income was $111.1 million in Q3 2025, or $3.86 per diluted share.”
“GAAP net income was $90.3 million in Q2 2025, or $3.10 per diluted share.”
Breaks if: Operating income falls below $141.5 million in Q1 2026
Focus on improving operating income through cost management and operational efficiency to support profitability growth.
Management emphasized enhancing operating income in 5 quarters from 2025-Q2 to 2026-Q2. Operating income increased from $126.3M in 2025-Q2 to $146.8M in 2026-Q2, with EBITDA margin stable at about 21.7%. The company’s full-year 2026 EBITDA guidance of $618M to $642M aligns with this improving profitability trajectory, indicating delivery on this priority.
“Operating income was $146.8 million in Q2 2026, up from $126.3 million in Q2 2025.”
“Operating income was $141.5 million in Q1 2026, up from $113.5 million in Q1 2025.”
“Operating income was $153.3 million in Q4 2025, up from $125.4 million in Q4 2024.”
“Operating income was $141.8 million in Q3 2025, up from $112.3 million in Q3 2024.”
“Operating income was $126.3 million in Q2 2025, up from $113.5 million in Q2 2024.”
Breaks if: YoY revenue growth falls below 6% in FY26
Continue to grow revenue through backlog conversion and new business awards to achieve full-year revenue guidance.
Stated as a priority in all 5 quarters from 2025-Q2 through 2026-Q2. Revenue grew from $603.3M in 2025-Q2 to $707.3M in 2026-Q2 (+17.2%), backlog increased 4.9% year-over-year as of 2026-Q2, and net new business awards increased notably. The company maintains 2026 revenue guidance of $2.805B to $2.885B, reflecting a trajectory delivering consistent revenue growth.
“Revenue of $707.3 million in Q2 2026 increased 17.2% from prior year; backlog increased 4.9%.”
“Revenue of $706.6 million in Q1 2026 increased 26.5% from prior year; backlog increased 2.9%.”
“Revenue of $708.5 million in Q4 2025 increased 32.0% from prior year; backlog increased 4.3%.”
“Revenue of $659.9 million in Q3 2025 increased 23.7% from prior year; backlog increased 2.5%.”
“Revenue of $603.3 million in Q2 2025 reported in prior periods with growth trends.”
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a stable growth opportunity, as MEDP focuses on increasing revenue and enhancing profitability. The current thesis is supported by strong financial performance and management's commitment to growth.
The market seems to have priced in a neutral valuation, with expectations slightly below current performance. MEDP is trading at a premium compared to its peers, indicating that investors are expecting consistent execution and growth.
Fundamentals are likely to continue improving, as management has successfully increased revenue and operating income. However, there is a moderate risk due to past misses and recent management transitions, which could impact future performance.
The thesis hinges on maintaining revenue growth and profitability while navigating potential macroeconomic challenges. Key factors include the performance of sector bellwethers and any changes in guidance during upcoming earnings calls.
Overall, MEDP's fundamentals and management execution support a positive outlook for the next 1 to 3 years. Not investment advice.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports a positive outlook. Additionally, the company raised its guidance, indicating strong revenue growth potential. These factors reinforce the thesis that the reason to own it remains intact.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.